Continuing benralizumab treatment after a previous study
Treatments studied
Part of Blood & lymphatic, Heart & circulation, Immune system & allergy, Lungs & breathing, Skin clinical trials.
This trial lets people who completed an earlier benralizumab study and are benefiting from the medicine keep receiving it. The goal is to provide ongoing access while we continue to monitor safety and effectiveness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You completed the required open-label extension period in a prior benralizumab study.
- The study doctor believes you are benefiting from continued benralizumab treatment.
- You do not have access to benralizumab through your local pharmacy or healthcare system.
- You agree to follow contraception rules (if needed) for up to 12 weeks after your last dose.
- You do not have any ongoing serious side effects from the previous study that would prevent restarting benralizumab.
- You are not planning to receive live vaccines or certain other biologic medications during the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medicine called benralizumab for children with specific eosinophil-driven diseases (EGPA or HES). It aims to see if the drug can help control these conditions.
This trial tests reslizumab, a medicine that targets a specific immune signal, to improve symptoms in people with eosinophilic granulomatosis with polyangiitis (EGPA). It may help lower disease activity and reduce inflammation-related problems.
This study tests a new way to take asthma medicine using a device that tracks your inhaler use. If you already use Fasenra (benralizumab) for severe asthma, you may be able to join.
This trial tests whether stopping omalizumab for a short time (or using it differently) can be safe for adults with severe allergic asthma who are doing well. It may help some people avoid long-term injections, but only if asthma remains well controlled.
This study follows people with severe eosinophilic asthma who are starting benralizumab. It looks at how well the treatment works in real life, outside of a controlled research setting.
This study looks at people in China with severe eosinophilic asthma who are starting a new medicine called benralizumab. It will collect information about their symptoms and quality of life to understand who benefits most.
Hear when a new Asthma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.